The Invisible Product: Preferences for Sustained-Release, Long-Acting Pre-exposure Prophylaxis to HIV Among South African Youth

被引:38
|
作者
Montgomery, Elizabeth T. [1 ]
Atujuna, Millicent [2 ]
Krogstad, Emily [1 ]
Hartmann, Miriam [1 ]
Ndwayana, Sheily [2 ]
O'Rourke, Shannon [1 ]
Bekker, Linda-Gail [2 ]
van der Straten, Ariane [1 ,3 ]
Minnis, Alexandra M. [1 ,4 ]
机构
[1] RTI Int, Ctr Global Hlth SSES, Womens Global Hlth Imperat, San Francisco Project Off, San Francisco, CA USA
[2] Desmond Tutu HIV Res Ctr, Cape Town, South Africa
[3] Univ Calif San Francisco, Ctr AIDS Prevent Studies, Dept Med, San Francisco, CA 94143 USA
[4] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA
关键词
South Africa; youth; PrEP; sustained-release long-acting PrEP; implants; injections; DAPIVIRINE VAGINAL RING; PREVENTION; ACCEPTABILITY; TRIAL;
D O I
10.1097/QAI.0000000000001960
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Long-acting injectable and implantable approaches aim to overcome some of the documented challenges with uptake and adherence to current HIV prevention methods. Youth are a key end-user population for these methods. We used qualitative methods to examine product attributes and preferences for current and future long-acting HIV prevention approaches. Methods: Ninety-five South African youth aged 18-24 years, of whom 62 were female and 33 male, completed 50 interviews and 6 focus groups. We purposively selected for previous product experience, including oral pre-exposure prophylaxis, injectable pre-exposure prophylaxis, or the vaginal ring, to ensure participants' opinions were rooted in actual experience. Results: Irrespective of previous method-use experience, gender, or sexual orientation, the majority expressed a preference for prevention methods formulated as injectables or implants. Several mentioned that their top priority in any product was efficacy, and for some, this overrode other concerns; for example, even if they feared pain, an implant or an injectable would be used if fully protective. Although efficacy was a top priority, there was also a clear desire across all subgroups for a product that would not interfere with sex, would stay in the system to provide protection, and that caused minimal burden, or was not apparent to others, and these characteristics were most salient for long-acting methods. Conclusions: Narrative explanations for preferences converged thematically around different dimensions of "invisibility" including invisibility to oneself, one's partner and household members, and community members. End-user preferences can be used to inform product development of long-acting HIV prevention approaches formulated as injections or implants to optimize adherence and impact.
引用
收藏
页码:542 / 550
页数:9
相关论文
共 50 条
  • [41] Preparing for the Implementation of Long-Acting InjectableCabotegravir for HIV Pre-Exposure Prophylaxis Within theBrazilian Public Health System (ImPrEP CAB Brasil):QualitativeStudy
    Pimenta, M. Cristina
    Torres, Thiago Silva
    Hoagland, Brenda
    Cohen, Mirian
    Mann, Claudio Gruber
    Jalil, Cristina M.
    Carvalheira, Eduardo
    Freitas, Lucilene
    Fernandes, Nilo
    Castanheira, Debora
    Benedetti, Marcos
    Moreira, Julio
    Simpson, Keila
    Trefiglio, Roberta
    O'Malley, Gabrielle
    Veloso, Valdilea G.
    Grinsztejn, Beatriz
    JMIR PUBLIC HEALTH AND SURVEILLANCE, 2024, 10 : e60961
  • [42] Long-term HIV Pre-exposure Prophylaxis Trajectories Among Racial & Ethnic Minority Patients: Short, Declining, & Sustained Adherence
    Pyra, Maria
    Brewer, Russell
    Rusie, Laura
    Kline, Jeanelle
    Willis, India
    Schneider, John
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2022, 89 (02) : 166 - 171
  • [43] HIV Pre-exposure Prophylaxis Implant Stated Preferences and Priorities: Results of a Discrete Choice Experiment Among Women and Adolescent Girls in Gauteng Province, South Africa
    Little, Kristen M.
    Flomen, Lola
    Hanif, Homaira
    Anderson, Sharon M.
    Thurman, Andrea R.
    Clark, Meredith R.
    Doncel, Gustavo F.
    AIDS AND BEHAVIOR, 2022, 26 (09) : 3099 - 3109
  • [44] Exploring preferences and decision-making about long-acting injectable HIV pre-exposure prophylaxis (PrEP) among young sexual minority men 17-24 years old
    John, Steven A.
    Zapata, Juan P.
    Dang, Madeline
    Pleuhs, Benedikt
    O'Neil, Andrew
    Hirshfield, Sabina
    Walsh, Jennifer L.
    Petroll, Andrew E.
    Quinn, Katherine G.
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [45] Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial
    Marzinke, Mark A.
    Hanscom, Brett
    Wang, Zhe
    Safren, Steven A.
    Psaros, Christina
    Donnell, Deborah
    Richardson, Paul A.
    Sullivan, Philip
    Eshleman, Susan H.
    Jennings, Andrea
    Feliciano, Kailazarid Gomez
    Jalil, Emilia
    Coutinho, Carolina
    Cardozo, Nadir
    Maia, Bernardo
    Khan, Taimur
    Singh, Yashna
    Middelkoop, Keren
    Franks, Julie
    Valencia, Javier
    Sanchez, Naiymah
    Lucas, Jonathan
    Rooney, James F.
    Rinehart, Alex R.
    Ford, Susan
    Adeyeye, Adeola
    Cohen, Myron S.
    McCauley, Marybeth
    Landovitz, Raphael J.
    Grinsztejn, Beatriz
    LANCET HIV, 2023, 10 (11): : E703 - E712
  • [46] Evaluation of Xpert point-of-care assays for detection of HIV infection in persons using long-acting cabotegravir for pre-exposure prophylaxis
    Fogel, Jessica M.
    Piwowar-Manning, Estelle
    Moser, Amber
    Hill, Tinia
    Ahmed, Shahnaz
    Cummings, Vanessa
    Mostafa, Heba H.
    Wang, Zhe
    Jennings, Andrea
    Gallardo-Cartagena, Jorge A.
    Figueroa, Maria Ines
    St Clair, Marty
    Rinehart, Alex R.
    Adeyeye, Adeola
    Rooney, James F.
    Cohen, Myron S.
    Grinsztejn, Beatriz
    Landovitz, Raphael J.
    Eshleman, Susan H.
    MICROBIOLOGY SPECTRUM, 2024, 12 (08):
  • [47] Pre-exposure prophylaxis for HIV prevention preferences among young adult African American men who have sex with men
    Patel, Rupa R.
    Crane, John S.
    Lopez, Julia
    Chan, Philip A.
    Liu, Albert Y.
    Tooba, Rubabin
    James, Aimee S.
    PLOS ONE, 2018, 13 (12):
  • [48] Preferences for long-acting pre-exposure prophylaxis among gay, bisexual and other men who have sex with men in Taiwan: findings from the 2021 HEART Survey
    Hsu, Jing-Hao
    Ku, Stephane Wen-Wei
    Chen, Tsai-Wei
    Li, Chia-Wen
    Huang, Poyao
    Wu, Huei-Jiuan
    Bourne, Adam
    Strong, Carol
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2023, 26 (09)
  • [49] Qualitative Consumer Research on Acceptance of Long-Acting Pre-Exposure Prophylaxis Products Among Men Having Sex with Men and Medical Practitioners in the United States
    Calder, Bobby J.
    Schieffer, Robert J.
    Tfaily, Ewa Bryndza
    D'Aquila, Richard
    Greene, George J.
    Carballo-Dieguez, Alex
    Giguere, Rebecca
    Kiser, Patrick F.
    Hope, Thomas J.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2018, 34 (10) : 849 - 856
  • [50] Uptake and retention on HIV pre-exposure prophylaxis among key and priority populations in South-Central Uganda
    Kagaayi, Joseph
    Batte, James
    Nakawooya, Hadijja
    Kigozi, Boniface
    Nakigozi, Gertrude
    Stromdahl, Susanne
    Ekstrom, Anna Mia
    Chang, Larry W.
    Gray, Ron
    Reynolds, Steven J.
    Komaketch, Patrick
    Alamo, Stella
    Serwadda, David
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 (08)